Follow
Mario de la Fuente Revenga
Mario de la Fuente Revenga
VCU Health
Verified email at vcuhealth.org
Title
Cited by
Cited by
Year
Deep eutectic solvents (DESs) are viable cosolvents for enzyme-catalyzed epoxide hydrolysis
D Lindberg, M de la Fuente Revenga, M Widersten
Journal of biotechnology 147 (3-4), 169-171, 2010
2502010
Synaptopathies: synaptic dysfunction in neurological disorders–A review from students to students
K Lepeta, MV Lourenco, BC Schweitzer, PV Martino Adami, P Banerjee, ...
Journal of neurochemistry 138 (6), 785-805, 2016
2152016
Ayahuasca: Pharmacology, neuroscience and therapeutic potential
E Domínguez-Clavé, J Soler, M Elices, JC Pascual, E Álvarez, ...
Brain research bulletin 126, 89-101, 2016
1992016
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
KPC Kuypers, J Riba, M De La Fuente Revenga, S Barker, ...
Psychopharmacology 233 (18), 3395-3403, 2016
1382016
The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro
JA Morales-García, M De la Fuente Revenga, S Alonso-Gil, ...
Scientific reports 7 (1), 1-13, 2017
1232017
Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities
F Sampedro, M de la Fuente Revenga, M Valle, N Roberto, ...
International Journal of Neuropsychopharmacology 20 (9), 698-711, 2017
1142017
Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects
D Ibi, M de la Fuente Revenga, N Kezunovic, C Muguruza, JM Saunders, ...
Nature neuroscience 20 (9), 1247-1259, 2017
612017
Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic …
M de la Fuente Revenga, N Fernandez-Saez, C Herrera-Arozamena, ...
Journal of Medicinal Chemistry 58 (12), 4998-5014, 2015
402015
Recent advances in neurogenic small molecules as innovative treatments for neurodegenerative diseases
C Herrera-Arozamena, O Martí-Marí, M Estrada, M De la Fuente Revenga, ...
Molecules 21 (9), 1165, 2016
362016
Temperature and pH Dependence of Enzyme-Catalyzed Hydrolysis of trans-Methylstyrene Oxide. A Unifying Kinetic Model for Observed Hysteresis, Cooperativity …
D Lindberg, M de la Fuente Revenga, M Widersten
Biochemistry 49 (10), 2297-2304, 2010
352010
Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice
M de la Fuente Revenga, B Zhu, CA Guevara, LB Naler, JM Saunders, ...
Cell reports 37 (3), 109836, 2021
312021
Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: New dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease
A Samadi, M de la Fuente Revenga, C Pérez, I Iriepa, I Moraleda, ...
European journal of medicinal chemistry 67, 64-74, 2013
312013
Neurogenic Potential Assessment and Pharmacological Characterization of 6-Methoxy-1, 2, 3, 4-tetrahydro-β-carboline (Pinoline) and Melatonin–Pinoline Hybrids
M de la Fuente Revenga, C Perez, JA Morales-Garcia, S Alonso-Gil, ...
ACS Chemical Neuroscience 6 (5), 800-810, 2015
272015
Cell-type-specific brain methylomes profiled via ultralow-input microfluidics
S Ma, M de la Fuente Revenga, Z Sun, C Sun, TW Murphy, H Xie, ...
Nature biomedical engineering 2 (3), 183-194, 2018
262018
Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo
M de la Fuente Revenga, JM Shin, HZ Vohra, KS Hideshima, M Schneck, ...
Scientific reports 9 (1), 1-14, 2019
252019
The melatonin analog IQM316 may induce adult hippocampal neurogenesis and preserve recognition memories in mice
J Figueiro-Silva, D Antequera, C Pascual, M de la Fuente Revenga, ...
Cell Transplantation 27 (3), 423-437, 2018
212018
HDAC2-dependent Antipsychotic-like Effects of Chronic Treatment with the HDAC Inhibitor SAHA in Mice
M de la Fuente Revenga, D Ibi, JM Saunders, T Cuddy, MK Ijaz, ...
Neuroscience 388, 102-117, 2018
192018
Differences in 5-HT2A and mGlu2 receptor expression levels and repressive epigenetic modifications at the 5-HT2A promoter region in the Roman low-(RLA-I) and high-(RHA-I …
L Fomsgaard, JL Moreno, M de la Fuente Revenga, T Brudek, ...
Molecular neurobiology 55 (3), 1998-2012, 2018
192018
Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity
M de la Fuente Revenga, D Ibi, T Cuddy, R Toneatti, M Kurita, MK Ijaz, ...
Neuropsychopharmacology 44 (2), 443-454, 2019
182019
New coumarin-based fluorescent melatonin ligands. Design, synthesis and pharmacological characterization
M de la Fuente Revenga, C Herrera-Arozamena, N Fernández-Sáez, ...
European journal of medicinal chemistry 103, 370-373, 2015
142015
The system can't perform the operation now. Try again later.
Articles 1–20